PharVision Advisers’s Aspen Aerogels ASPN Stock Holding History

PharVision Advisers’s Portfolio ASPN Stock Details ASPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-33,808	Closed	-$95.7K	–	139
2025 Q4	$95.7K	Buy	+33,808	New	+$174K	0.05%	659

Other funds holding ASPN

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

OCMI

Oaktop Capital Management II Chatham, New Jersey $1.34B AUM 114.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GKFF

George Kaiser Family Foundation Tulsa, Oklahoma $883M AUM 21.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

PharVision Advisers's ASPN Position: Q1 2026 in Review

PharVision Advisers sold out of Aspen Aerogels (ASPN) in Q1 2026, closing a stake of 33,808 shares — an estimated $95.7K sold.

PharVision Advisers first reported a position in ASPN in Q4 2025 and held it in 1 quarter. The position peaked at $95.7K in Q4 2025. 166 funds tracked by Wall St. Rank hold ASPN as of Q1 2026.

PharVision Advisers reported no remaining Aspen Aerogels position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 33,808 Aspen Aerogels shares in Q1 2026, an estimated $95.7K.
PharVision Advisers first reported a position in Aspen Aerogels in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Aspen Aerogels position peaked at $95.7K in Q4 2025.
166 funds tracked by Wall St. Rank held Aspen Aerogels as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.